Recently, a study focused on the mechanisms other than COX-2 found that celecoxib’s anti-tumor effect on HCC might also involve partner of NOB1 (PNO1) and AKT/rapamycin (mTOR) signaling pathway (49). The gene discussed is AKT1; the disease is hepatocellular carcinoma.